The science, economics, and effectiveness of combination therapy for hepatitis C - Wikidata - wikimedia - TriplyDB

The science, economics, and effectiveness of combination therapy for hepatitis C

The science, economics, and effectiveness of combination therapy for hepatitis C

http://www.wikidata.org/entity/Q27477845

about

Basic answers to complicated questions for the course of chronic hepatitis C treatment.Interferon-beta plus ribavirin for patients with hepatitis C virus genotype 1: a randomised pilot trial

P2860

Q38014499-EE5896A7-1DA8-494D-A5D8-02CB349662B4 Q42844274-1AF3A282-E82B-4A7C-9C10-820DF3505352

P2860

The science, economics, and effectiveness of combination therapy for hepatitis C

http://www.wikidata.org/entity/Q27477845

description

2000 nî lūn-bûn

@nan

2000 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2000 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2000年の論文

@ja

2000年論文

@yue

2000年論文

@zh-hant

2000年論文

@zh-hk

2000年論文

@zh-mo

2000年論文

@zh-tw

2000年论文

@wuu

name

The science, economics, and effectiveness of combination therapy for hepatitis C

@ast

The science, economics, and effectiveness of combination therapy for hepatitis C

@en

The science, economics, and effectiveness of combination therapy for hepatitis C

@nl

type

label

The science, economics, and effectiveness of combination therapy for hepatitis C

@ast

The science, economics, and effectiveness of combination therapy for hepatitis C

@en

The science, economics, and effectiveness of combination therapy for hepatitis C

@nl

prefLabel

The science, economics, and effectiveness of combination therapy for hepatitis C

@ast

The science, economics, and effectiveness of combination therapy for hepatitis C

@en

The science, economics, and effectiveness of combination therapy for hepatitis C

@nl

P1433

Q27477845-6AEE134B-3FA4-4859-91FC-B092166EF641

P1476

Q27477845-BFD6843F-1938-4AA8-9B68-19DF8385CB54

P2093

Q27477845-53FF0328-F55D-41B5-A41E-690EDA8936FA

Q27477845-544A7192-D56B-48E4-BF72-6656E7B1BF09

Q27477845-6196470C-0D67-47F3-AC9F-31AAEA8A0884

Q27477845-9FAD2762-8B4E-4FC2-B0E4-E219044E9998

P2860

Q27477845-174D822B-D54E-4F25-AA13-2FEB1A9D8207

Q27477845-29E940B0-196D-4079-B482-54B04356724F

Q27477845-3FB5B39B-3569-4AEB-95EC-55D2366BD43B

Q27477845-45155F39-788F-4510-885E-E56527B35972

Q27477845-5D2D9079-4CFA-44D1-BDB7-46FE0FAC30B6

Q27477845-774C6310-47CE-4716-B6BD-D942B257C964

Q27477845-95F63D43-DB34-4BF7-A5AE-D8874801BB63

Q27477845-9A9A14C3-2A00-4001-92EB-9BFF760F3F58

Q27477845-B898BE68-8560-4B1C-98EE-0AF4491E7E3B

Q27477845-C28FAA22-C3C2-4D4C-A482-30A6ED01F660

P304

Q27477845-3482B149-A6FF-4BF8-8A09-4A2904FDD5DD

P31

Q27477845-EB022FBA-3CC2-4D34-A855-2EFB39EAC5D1

P356

Q27477845-4E4A2EC0-02A0-4E53-8B3B-0DF6BF1FEED9

P407

Q27477845-F9847FE5-5890-4D35-ABD5-1AA3DC0630E1

P433

Q27477845-95119205-F962-436A-B276-CAF9C55E9FD8

P478

Q27477845-7EA719AD-4D66-48E5-AAAC-09DC59354473

P577

Q27477845-DD8830CA-30B4-4E58-98D0-5CE0897EDD93

P5875

Q27477845-ADE71F81-10E8-452E-8E84-138FA85D55DA

P698

Q27477845-98FC3502-55C3-4474-B95C-A2C9DE09B0AA

P932

Q27477845-14E3A580-77A1-4CCB-ACC8-3675E12DFB30

P356

P1433

P1476

The science, economics, and effectiveness of combination therapy for hepatitis C

@en

P2093

E Barnes

http://www.w3.org/2001/XMLSchema#string

G Dusheiko

http://www.w3.org/2001/XMLSchema#string

G Webster

http://www.w3.org/2001/XMLSchema#string

S Whalley

http://www.w3.org/2001/XMLSchema#string

P2860

Imino sugars inhibit the formation and secretion of bovine viral diarrhea virus, a pestivirus model of hepatitis C virus: implications for the development of broad spectrum anti-hepatitis virus agents

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups

The prevalence of hepatitis C virus infection in the United States, 1988 through 1994

Combination therapy with interferon alfa and ribavirin as retreatment of interferon relapse in chronic hepatitis C.

Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions.

Sequence variability of hepatitis C virus and its clinical relevance.

An infectious molecular clone of a Japanese genotype 1b hepatitis C virus.

Epidemiological, clinical and therapeutic associations of hepatitis C types in western European patients.

Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study.

P304

159-61

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/GUT.47.2.159

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

47

http://www.w3.org/2001/XMLSchema#string

P577

2000-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

274417315

http://www.w3.org/2001/XMLSchema#string

P698

10896900

http://www.w3.org/2001/XMLSchema#string

P932

1728019

http://www.w3.org/2001/XMLSchema#string